AnaptysBio (ANAB) Stock Price & Analysis
ANAB Stock Chart & Stats
- Day’s Range
- MXN 668.00 - MXN 668.00
- 52-Week Range
- MXN 580.00 - MXN 668.00
- Previous Close
- MXN 668.00
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- MXN 27.11B
- Enterprise Value
- MXN 2.11B
- Total Cash (Recent Filing)
- MXN 164.14M
- Total Debt (Recent Filing)
- MXN 269.59M
- Price to Earnings (P/E)
- 7.2
- Beta
- -0.05
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Profitability And Revenue Inflection
The substantial improvement in revenue and profitability shows a meaningful earnings inflection versus prior loss-making periods. If the company can sustain collaboration economics and development progress, this stronger earnings base could support reinvestment and improve financial resilience over the next several quarters.
Positive Free Cash Flow
Positive operating and free cash flow represent a durable improvement in the company’s ability to fund operations internally rather than relying entirely on external financing. Continued cash generation would provide greater flexibility for antibody development, partnerships, and other strategic priorities.
Partnered Asset Regulatory Progress
FDA approval for a partnered immunotherapy expands the validated clinical and commercial scope of an asset connected to AnaptysBio’s collaboration portfolio. Such regulatory progress can strengthen the strategic value of the platform and support future collaboration-related economics, subject to agreement terms.
Bears Say
Compressed Balance-Sheet Cushion
Very low equity relative to debt leaves less balance-sheet protection against earnings volatility or unexpected cash needs. The sharp increase in debt-to-equity from prior years may constrain financial flexibility and make the company more sensitive to setbacks in development or collaboration-related cash flows.
Weak Cash Conversion
Although cash flow has turned positive, the gap between reported net income and operating cash generation raises questions about the durability and timing of earnings conversion. If this pattern persists, accounting profits may provide less dependable funding capacity for ongoing research and corporate needs.
Collaboration-Dependent Business Model
Dependence on collaborations and licensing makes revenue contingent on partner agreements, development milestones, and commercial outcomes rather than a diversified product base. With no marketed products, sustained financial performance remains exposed to the timing and success of partnered programs.
ANAB FAQ
What was AnaptysBio’s price range in the past 12 months?
What is AnaptysBio’s market cap?
When is AnaptysBio’s upcoming earnings report date?
How were AnaptysBio’s earnings last quarter?
Is AnaptysBio overvalued?
Does AnaptysBio pay dividends?
What is AnaptysBio’s EPS estimate?
How many shares outstanding does AnaptysBio have?
What happened to AnaptysBio’s price movement after its last earnings report?
Which hedge fund is a major shareholder of AnaptysBio?
What is the TipRanks Smart Score and how is it calculated?
AnaptysBio Stock Smart Score
Company Description
AnaptysBio
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Daniel Faga
- Employees
- 104
- Website
- www.anaptysbio.com
- Address
- 10770 Wateridge Circle, San Diego, CA, 92121, US
AnaptysBio (ANAB) Earnings & Revenues
ANAB Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 6 | 1 |
| Technical Analysis | 2 | 0 | 1 |
| Moving Averages | 6 | 6 | 0 |